Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NSC 631570

Drug Profile

NSC 631570

Alternative Names: NSC B238865; Ukrain; UKSR 222; W122

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nowicky Pharma
  • Developer Military Medical Academy; Nowicky Pharma; Ukrainian Anti-Cancer Institute
  • Class Antineoplastics; Berberine alkaloids; Phenanthridines
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer

Highest Development Phases

  • Marketed Cancer
  • No development reported Influenza virus infections; Pancreatic cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(Combination therapy, Late-stage disease) in Germany (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(Combination therapy, Late-stage disease) in Ukraine (IV, Infusion)
  • 10 Oct 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top